Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 12/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 9/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 9/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 9/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.35 |
| ▸ | TSHR | P16473 | 7/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 5/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21138164 | 0.97 | CYP2D6 (0.38) | CYP2D6CYP1A2HSD17B10ALDH1A1ADORA3 | |
| SCHEMBL21057382 | 0.86 | ADORA2A (0.39) | ADORA3PTPN11NUDT1 | |
| SCHEMBL21138852 | 0.86 | GRIA1 (0.40) | ADORA3PTPN11NUDT1 | |
| SCHEMBL21138812 | 0.84 | CYP2D6 (0.38) | CYP2D6CYP1A2HSD17B10ALDH1A1CYP2C19 | |
| SCHEMBL21138170 | 0.82 | ADORA3 (0.41) | ADORA3PTPN11NUDT1 | |
| SCHEMBL21138462 | 0.82 | ADORA3 (0.41) | ADORA3PTPN11NUDT1 | |
| SCHEMBL21138160 | 0.82 | ADORA3 (0.41) | ADORA3PTPN11NUDT1 | |
| SCHEMBL21138254 | 0.82 | CYP2D6 (0.38) | CYP2D6CYP1A2HSD17B10ALDH1A1CYP2C19 | |
| SCHEMBL21138854 | 0.81 | PTPN11 (0.44) | ADORA3PTPN11NUDT1 | |
| SCHEMBL21138466 | 0.77 | PTPN11 (0.45) | ADORA3PTPN11NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3505171-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2019-07-03 | — | — | EP | disclosed |
| US-20190185479-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185479-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | PDE7B, PDE3A, PDE7A | CYP2D6 1148/4885CYP1A2 917/4885HSD17B10 883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.